Abstract:Background: Enterovirus 71 (EV71) infection can lead to a rapidly progressing, life-threatening, and severe neurological disease in young children, including the development of human hand, foot, and mouth disease (HFMD). This study aims to further characterize the specific immunological features in EV71-mediated HFMD patients presenting with differing degrees of disease severity.Methodology: Comprehensive cytokine and chemokine expression were broadly evaluated by cytokine antibody array in EV71-infected patients hospitalized for HFMD compared to Coxsackievirus A16-infected patients and age-matched healthy controls. More detailed analysis using Luminex-based cytokine bead array was performed in EV71-infected patients stratified into diverse clinic outcomes. Additionally, immune cell frequencies in peripheral blood and EV71-specific antibodies in plasma were also examined.Principal Findings: Expression of several cytokines and chemokines were significantly increased in plasma from EV71-infected patients compared to healthy controls, which further indicated that: (1) GM-CSF, MIP-1b, IL-2, IL-33, and IL-23 secretion was elevated in patients who rapidly developed disease and presented with uncomplicated neurological damage; (2) G-CSF and MCP-1 were distinguishably secreted in EV71 infected very severe patients presenting with acute respiratory failure; (3) IP-10, MCP-1, IL-6, IL-8, and G-CSF levels were much higher in cerebrospinal fluid than in plasma from patients with neurological damage; (4) FACS analysis revealed that the frequency of CD19+ HLADR+ mature B cells dynamically changed over time during the course of hospitalization and was accompanied by dramatically increased EV71-specific antibodies. Our data provide a panoramic view of specific immune mediator and cellular immune responses of HFMD and may provide useful immunological profiles for monitoring the progress of EV71-induced fatal neurological symptoms with acute respiratory failure.

Design, Synthesis, and Evaluation of Novel Enterovirus 71 Inhibitors As Therapeutic Drug Leads for the Treatment of Human Hand, Foot, and Mouth Disease.

Discovery of Potent EV71 Capsid Inhibitors for Treatment of HFMD

Inhibition of Enterovirus 71 Replication by an Α-Hydroxy-nitrile Derivative NK-1.9k

Design, Synthesis, and Biological Evaluation of Anti-Ev71 Agents.

Studies on Inhibition of Proliferation of Enterovirus-71 by Compound YZ-LY-0

Identification of Dibucaine Derivatives As Novel Potent Enterovirus 2C Helicase Inhibitors: in Vitro, in Vivo, and Combination Therapy Study

Discovery of Novel Andrographolide Derivatives as Antiviral Inhibitors against Human Enterovirus A71

Characterization of Three Small Molecule Inhibitors of Enterovirus 71 Identified from Screening of a Library of Natural Products

Identification of Luteolin As Enterovirus 71 and Coxsackievirus A16 Inhibitors Through Reporter Viruses and Cell Viability-Based Screening

Advances in anti-EV-A71 drug development research

Identification of fangchinoline as a broad-spectrum enterovirus inhibitor through reporter virus based high-content screening

Lycorine Derivative LY-55 Inhibits EV71 and CVA16 Replication Through Downregulating Autophagy

Discovery of Aminothiazole Derivatives As Novel Human Enterovirus A71 Capsid Protein Inhibitors

Identification and Structure–Activity Relationships of Diarylhydrazides as Novel Potent and Selective Human Enterovirus Inhibitors

Structure of the Enterovirus 71 3C Protease in Complex with NK-1.8k and Indications for the Development of Antienterovirus Protease Inhibitor

Comparative Study of the Cytokine/Chemokine Response in Children with Differing Disease Severity in Enterovirus 71-Induced Hand, Foot, and Mouth Disease

Recent progress and challenges in drug development to fight hand, foot and mouth disease

An adenosine nucleoside analogue NITD008 inhibits EV71 proliferation

CUR-N399, a PI4KB inhibitor, for the treatment of Enterovirus A71 infection

In vitro discovery of a therapeutic lead for HFMD from a library screen of rocaglates/aglains

Antiviral activity of the HSP90 inhibitor VER-50589 against enterovirus 71